PSP Research LLC Makes New $534,000 Investment in Roivant Sciences Ltd. $ROIV

PSP Research LLC bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 24,621 shares of the company’s stock, valued at approximately $534,000.

Several other institutional investors and hedge funds have also bought and sold shares of ROIV. Goldman Sachs Group Inc. increased its holdings in shares of Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after buying an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after buying an additional 34,341 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Roivant Sciences by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after buying an additional 1,689 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after buying an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp increased its holdings in shares of Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $28.21 on Wednesday. Roivant Sciences Ltd. has a 1 year low of $10.59 and a 1 year high of $30.33. The stock has a market cap of $20.19 billion, a P/E ratio of -24.11 and a beta of 1.14. The firm has a 50-day moving average of $28.38 and a 200 day moving average of $24.85.

Analyst Upgrades and Downgrades

ROIV has been the topic of several recent research reports. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 target price on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Guggenheim increased their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, February 9th. Citigroup increased their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Finally, Piper Sandler increased their target price on shares of Roivant Sciences from $22.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.55.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the transaction, the chief executive officer directly owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total transaction of $384,073.06. Following the transaction, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at $2,388,498.67. The trade was a 13.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,745,173 shares of company stock valued at $103,639,917. 10.80% of the stock is owned by company insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.